About Genomic Vision
Genomic Vision is a company based in Bagneux (France) founded in 2004. Genomic Vision has raised $8.3 million across 3 funding rounds from investors including Société Générale, European Union and Vesalius Biocapital Partners. Genomic Vision operates in a competitive market with competitors including Guardant Health, GRAIL, Foundation Medicine, ArcherDX and Natera, among others.
- Headquarter Bagneux, France
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$8.3 M (USD)
in 3 rounds
-
Latest Funding Round
$755.44 K (USD), Grant
May 01, 2015
-
Investors
Société Générale
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Genomic Vision
Genomic Vision has successfully raised a total of $8.3M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $755.44 thousand completed in May 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genomic Vision
Genomic Vision has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Société Générale, European Union and Vesalius Biocapital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences-focused VC firm investing in Europe and Canada
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Full-service corporate advisory is provided to global clients.
|
Locked | Locked | Locked |
Investor details for Genomic Vision
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genomic Vision
Investment portfolio details for Genomic Vision
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genomic Vision
Detailed financials for Genomic Vision
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genomic Vision Comparisons
Peer comparison for Genomic Vision
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genomic Vision
Genomic Vision operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Foundation Medicine, ArcherDX and Natera, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomic technologies and drug discovery platforms are provided.
|
Detailed competitors of Genomic Vision
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genomic Vision
Complete news archive for Genomic Vision
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genomic Vision
Genomic Vision was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Genomic Vision is headquartered in Bagneux, France. It is registered at Bagneux, Hauts-de-seine, France.
Genomic Vision is a funded company, having raised a total of $8.3M across 3 funding rounds to date.
Genomic Vision develops diagnostic and drug discovery solutions based on its nanotechnology for DNA analysis in the areas of cancer and acute diseases. These diagnostic tests and drug discovery tools operate where genome dynamics and human disease intersect. Genomic Vision uses a technique, Molecular Combing Technology, for the direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape and establish their contribution to pathology. GVs initial focus is towards early cancer detection and drug therapy monitoring. The company possesses a capability for discovering genomic biomarkers implicated in the predisposition and development of many forms of cancer and in following and analyzing DNA replication during cell division. This provides an approach for evaluating the efficacy of new drugs on the cell cycle.
Genomic Vision's top competitors include Guardant Health, GRAIL and Strand Life Sciences.
Genomic Vision has 3 investors. Key investors include Société Générale, European Union, and Vesalius Biocapital Partners.